Literature DB >> 22021534

Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.

Mi Hee Lee1, Seong Hyun Kim, Min Jung Park, Cheol Keun Park, Hyunchul Rhim.   

Abstract

OBJECTIVE: The purpose of this article is to evaluate the value of gadoxetic acid-enhanced hepatobiliary phase imaging and high-b-value diffusion-weighted imaging (DWI) for distinguishing well-differentiated hepatocellular carcinomas (HCCs) from benign hepatocellular nodules in patients with chronic liver disease using 3-T MRI.
MATERIALS AND METHODS: Forty-five patients with 46 well-differentiated HCCs (mean, 2.3 cm) and 21 patients with 24 benign hepatocellular nodules (five large regenerative nodules and 19 dysplastic nodules; mean, 1.8 cm) were included in this study. Diagnosis of well-differentiated HCCs and benign hepatocellular nodules was made histopathologically by percutaneous biopsy (n = 12 and n = 11, respectively) or surgical resection (n = 34 and n = 13, respectively). Gadoxetic acid-enhanced MRI was performed for all patients, and DWI (b values of 0 and 800 s/mm(2)) was performed for 31 well-differentiated HCCs and 11 benign hepatocellular nodules. Two radiologists performed a consensus review of the MRI scans for signal intensity compared with that of the surrounding liver parenchyma on hepatobiliary phase images and DWI (b value, 800 s/mm(2)) for qualitative analysis. The contrast-to-noise ratio (CNR) and relative contrast enhancement of lesions on hepatobiliary phase images and the apparent diffusion coefficient (ADC) values were assessed for quantitative analysis.
RESULTS: In the qualitative analysis, 39 well-differentiated HCCs (85%) and 14 benign hepatocellular nodules (58%) were hypointense on hepatobiliary phase images, and seven well-differentiated HCCs (15%) and 10 benign hepatocellular nodules (42%) were iso- or hyperintense (p = 0.04). Twenty-five well-differentiated HCCs (81%) and three benign hepatocellular nodules (27%) were hyperintense on DWI, with b value of 800 s/mm(2), and six well-differentiated HCCs (19%) and eight benign hepatocellular nodules (73%) were iso- or hypointense (p = 0.01). When lesion hypointensity on hepatobiliary phase images or hyperintensity on DWI were considered signs of HCC in cirrhotic liver, our results yielded sensitivities of 85% and 81% and specificities of 42% and 73%, respectively. In the quantitative analysis, the mean (± SD) relative contrast enhancement ratio of the well-differentiated HCCs (0.76 ± 2.30) was significantly higher than that of benign hepatocellular nodules (0.25 ± 0.97) (p = 0.02). The lesion-to-liver CNRs and the mean ADC values were not significantly different between the two groups (p > 0.05).
CONCLUSION: Hypointensity on gadoxetic acid-enhanced hepatobiliary phase images and hyperintensity on high-b-value DWI to surrounding liver parenchyma suggest well-differentiated HCCs rather than benign hepatocellular nodules in chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021534     DOI: 10.2214/AJR.10.6237

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  46 in total

1.  Diffusion-weighted images (DWI) without ADC values in assessment of small focal nodules in cirrhotic liver.

Authors:  Mai-Lin Chen; Xiao-Yan Zhang; Li-Ping Qi; Qing-Lei Shi; Bin Chen; Ying-Shi Sun
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

Review 2.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

Review 3.  Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid.

Authors:  Francesco Agnello; Marco Dioguardi Burgio; Dario Picone; Federica Vernuccio; Giuseppe Cabibbo; Lydia Giannitrapani; Adele Taibbi; Antonino Agrusa; Tommaso Vincenzo Bartolotta; Massimo Galia; Roberto Lagalla; Massimo Midiri; Giuseppe Brancatelli
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

5.  Giant hepatic regenerative nodules in Alagille syndrome.

Authors:  Jordan B Rapp; Richard D Bellah; Carolina Maya; Bruce R Pawel; Sudha A Anupindi
Journal:  Pediatr Radiol       Date:  2016-10-28

6.  Diffusion-weighted MRI in intrahepatic bile duct adenoma arising from the cirrhotic liver.

Authors:  Chansik An; Sumi Park; Yoon Jung Choi
Journal:  Korean J Radiol       Date:  2013-08-30       Impact factor: 3.500

7.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

9.  Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.

Authors:  Massimo Galia; Francesco Agnello; Gianvincenzo Sparacia; Domenica Matranga; Domenico Albano; Massimo Midiri; Roberto Lagalla
Journal:  Radiol Med       Date:  2018-03-15       Impact factor: 3.469

Review 10.  Diffusion-weighted imaging of the liver: techniques and applications.

Authors:  Sara Lewis; Hadrien Dyvorne; Yong Cui; Bachir Taouli
Journal:  Magn Reson Imaging Clin N Am       Date:  2014-08       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.